AstraZeneca PLC Director/PDMR Shareholding (8429K)
September 26 2016 - 10:00AM
UK Regulatory
TIDMAZN
RNS Number : 8429K
AstraZeneca PLC
26 September 2016
26 September 2016 16:00
Transaction by Person Discharging Managerial
Responsibilities
Disclosure Rule DTR 3.1.4
On 26 September 2016, the interest of Sean Bohen, a person
discharging managerial responsibilities, in the ordinary shares of
AstraZeneca PLC changed as detailed below.
The change in interest relates to the vesting of an award of
AstraZeneca American Depositary Shares (ADSs) made in September
2015 under the AstraZeneca Restricted Share Plan.
One ordinary share equals two ADSs.
After sufficient vested shares were withheld to satisfy certain
tax obligations arising on the vesting, Mr Bohen has become
beneficially entitled to and has received 12,385 ADSs into a
personal brokerage account.
For tax purposes, the fair market value of the shares at vest
was $33.97 per ADS being the closing price on the last trading day
preceding the vesting day.
The attached notification, made in accordance with the
requirements of the EU Market Abuse Regulation, gives further
detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Name Sean Bohen
--- ------------------------- ------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Executive Vice-President,
Global Medicines Development
and Chief Medical Officer
--- ------------------------- ------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------- ------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ---------------------------------------------------------------
a) Name AstraZeneca PLC
--- ------------------------- ------------------------------------
b) LEI Not applicable
--- ------------------------- ------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ---------------------------------------------------------------
a) Description of AstraZeneca PLC American
the financial Depositary Shares
instrument, type
of instrument
Identification CUSIP: 046353108
code
--- ------------------------- ------------------------------------
b) Nature of the Acquisition of AstraZeneca
transaction American Depositary Shares
pursuant to the vesting of
an award under the AstraZeneca
Restricted Share Plan
--- ------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
$33.97 12,385
--------- ----------
--- ------------------------- ------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
--- ------------------------- ------------------------------------
e) Date of the transaction 26 September 2016
--- ------------------------- ------------------------------------
f) Place of the transaction New York
--- ------------------------- ------------------------------------
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Respiratory and Autoimmunity, Cardiovascular
and Metabolic Diseases, and Oncology. The Company is also active in
inflammation, infection and neuroscience through numerous
collaborations. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.
For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Neil Burrows UK/Global +44 203 749 5637
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
+46 8 553 260
Jacob Lund Sweden 20
Michele Meixell US +1 302 885 2677
Investor Relations
UK
Thomas Kudsk
Larsen +44 203 749 5712
Finance, Fixed +44 7881 615
Craig Marks Income, M&A 764
Respiratory &
Nick Stone Autoimmunity +44 203 749 5716
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris Infection & Neuroscience +44 203 749 5711
US
Cardiovascular
Lindsey Trickett & Metabolic Diseases +1 240 543 7970
Mitchell Chan Oncology +1 240 477 3771
Toll-free +1 866 381 7277
Adrian Kemp
Company Secretary
AstraZeneca PLC
-ENDS-
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUNUORNOAKUAR
(END) Dow Jones Newswires
September 26, 2016 11:00 ET (15:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025
